Chemokines: established and novel targets in atherosclerosis

EMBO Molecular Medicine - Tập 3 Số 12 - Trang 713-725 - 2011
Rory R. Koenen1,2, Christian Weber1,2
1Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands
2Institute for Cardiovascular Prevention, Ludwig-Maximilians-University of Munich, Munich, Germany

Tóm tắt

AbstractIn their role as small chemotactic cytokines, chemokines are crucial mediators and regulators of leukocyte trafficking during immune surveillance and inflammation. Their involvement in the development and progression of inflammatory diseases has been subject of intense investigation. Concordantly, the chemokine system has been explored in search for therapeutic targets to prevent or treat inflammatory disorders, such as atherosclerosis. Targeting the chemokine system offers various entry points for a causative treatment of this widespread and chronic illness. Although this approach has encountered some setbacks, several innovative compounds are currently in an advanced stage of development. In this review, the current standing of this dynamic field is highlighted and the potential advantages and drawbacks of particular strategies are discussed.

Từ khóa


Tài liệu tham khảo

10.1016/j.atherosclerosis.2009.08.017

10.1038/nm1343

10.4049/jimmunol.166.1.552

10.1111/j.1600-6143.2009.02868.x

10.1161/CIRCULATIONAHA.105.540583

10.1016/j.immuni.2010.10.018

10.1172/JCI41732

10.1038/nbt1127

10.1172/JCI1195

10.2353/ajpath.2006.040748

10.1038/29788

10.1161/ATVBAHA.108.165423

10.1016/j.yjmcc.2009.07.029

10.1016/S0165-5728(02)00106-6

10.4049/jimmunol.177.10.6991

10.1056/NEJMra052723

10.1038/nrd3444

10.1096/fasebj.9.1.7821760

10.1073/pnas.0804286105

10.1371/journal.pone.0010510

10.1084/jem.20072689

10.1371/journal.pone.0008514

10.1189/jlb.0308158

10.1161/CIRCULATIONAHA.110.961714

10.1038/nature08938

10.1038/nri2297

10.1073/pnas.0805098105

10.1161/CIRCULATIONAHA.106.678474

10.1189/jlb.0602269

10.1161/ATVBAHA.108.180505

10.1160/TH11-01-0020

10.1016/j.amjcard.2010.11.005

10.1182/blood-2009-08-240580

10.1084/jem.181.2.631

10.1189/jlb.0108061

10.1038/ni.2001

10.1002/art.21975

10.1161/CIRCULATIONAHA.105.605121

10.1021/bi971125s

10.1038/nrd2734

10.1160/TH10-05-0308

10.1111/j.1538-7836.2008.03086.x

10.1016/j.yexcr.2010.10.020

10.1038/nrd3048

10.1038/nm.1898

10.1016/j.yexcr.2010.11.014

10.1371/journal.pone.0001110

10.1086/527327

10.1182/blood-2008-07-170787

10.1172/JCI15555

10.1016/j.jacc.2010.04.066

10.1182/blood-2010-01-261206

10.1161/CIRCULATIONAHA.110.956730

10.1160/TH07-01-0035

10.1172/JCI8125

10.1161/CIRCULATIONAHA.104.510073

10.1378/chest.126.3.926

10.1016/S0167-5699(99)01469-3

10.1016/S1074-7613(03)00263-2

10.1074/jbc.271.32.19084

10.1161/ATVBAHA.110.206011

10.1093/eurheartj/ehr1127

10.1161/01.ATV.0000259365.31469.89

10.1016/j.yexcr.2010.11.016

10.1016/S0021-9258(18)53154-9

10.1161/ATVBAHA.107.147009

10.1194/jlr.R400001-JLR200

10.1096/fj.09-134643

10.1074/jbc.M109.043299

10.1111/j.1582-4934.2008.00223.x

10.1172/JCI43802

10.1074/jbc.271.5.2599

10.1073/pnas.0334864100

10.1038/ni.1675

10.1016/j.yexcr.2011.01.005

10.1161/CIRCULATIONAHA.106.631457

10.1038/emboj.2010.256

10.1371/journal.pone.0022526

10.1016/j.yexcr.2011.01.016

10.1146/annurev.immunol.22.012703.104543

10.1016/j.yexcr.2011.01.004

10.1038/nri2972

10.1084/jem.20061405

10.1161/01.CIR.0000028590.02477.6F

10.1038/ni1309

10.1111/j.1582-4934.2009.00979.x

10.1084/jem.20050955

10.1038/nri2779

10.1074/jbc.M109.054809

10.1046/j.1523-1755.2002.00148.x

10.1172/JCI29950

10.1172/JCI28549

10.1073/pnas.0511043103

10.1172/JCI29919

10.1161/01.ATV.0000192018.90021.c0

10.1161/ATVBAHA.107.147827

10.1161/01.RES.0000109793.17591.4E

10.1161/CIRCULATIONAHA.104.520718

10.1182/blood-2004-06-2475

10.1080/10739680802564787

10.1161/CIRCRESAHA.111.242578

10.1038/ni1233

10.1038/nri2415

10.1172/JCI44925

10.1016/j.tips.2005.11.001

10.1002/art.25497

10.1093/cvr/cvp391

10.1161/CIRCRESAHA.107.160697